Here are 3 articles that I find exciting about potential breakthrough findings dealing with prostate cancer patients. Most patients like myself has tried or will be trying Zytiga or Xtandi for PSA control. Article #1 states (39 percent) Among the men treated with enzalutamide had detectable AR-V7 in circulating tumor cells and Among the men treated with abiraterone acetate (19 percent) had detectable AR-V7 in circulating tumor cells. Article# 2 states Denosumab, similar to Zometa is associated with a rare but well-known risk for severe hypocalcemia. Article #3 states a new form of prostate cancer immunotherapy test (ADXS-PSA) in combination with an investigational drug called pembrolizumab
Early reports that prostate cancer patients carrying the androgen receptor subtype known as AR-V7 (the “isoform” encoded by splice variant 7) exhibit a high level of resistance to treatment with both enzalutamide (Xtandi) and abiraterone acetate (Zytiga). Full story: AR-V7 and resistance to treatment with enzalutamide,
#2 Denosumab — marketed as Xgeva and as Prolia — is associated with a rare but well-known risk for severe hypocalcemia (very low calcium in the blood stream). Sept.3 2014
A recent case study reported by Muqeet Adnan et al. emphasizes the importance of patients having their serum levels of vitamin D and calcium checked prior to any initial administration of denosumab for the prevention of bone loss and other skeletal-related events. Full Story: Denosumab therapy and risk for severe hypocalcemia
#3 New form of prostate cancer immunotherapy test (ADXS-PSA) Aug. 25 2014
PD-1 inhibitors work by blocking the effects of a protein called PD-1 (formally known as the programmed cell death 1 protein), which normally controls the growth and release of immune system cells, thus making it easier for immune system cells to attack invading cancer cells.
Life is the death sentence, not the disease !
The New Denver Men’s Club
Blog: https://newdenvermensclub.wordpress.com/ “Men Fighting Cancer To Win”
You can read all my posts at the blog site by clicking here